HUVY
Book a demo
First Class IIb CE-certified medical device in Europe

Detect early.
Optimize orientation.
Provide enhanced protection

HUVY assists primary healthcare professionals in assessing the melanoma risk of a mole within seconds, powered by a CE Class IIb certified AI. Without establishing a diagnosis, HUVY helps refer each patient to the right specialist at the right time, in accordance with the established care pathway.

Book a demoLearn more
CE classe IIbPremier dispositif médical certifié CE IIb en Europe 0 % · 0 %de sensibilité et de spécificité Comité scientifique indépendantDermatologues hospitalo-universitaires 4 études cliniquesPré et post-commercialisation, sur plus de 3 000 lésions, menées avec le CHU de Nantes

A public health concern

Taking early action against melanoma and streamlining the dermatological care pathway

~20%

Projected Increase in Melanoma Incidence by 2040

An increase anticipated due to population aging and UV exposure habits

View source

~99 %

5-Year Survival Rate with Early Detection

At Stage I, the 5-year survival rate is near 100%. At Stage IV (metastatic), it drops to approximately 30% or lower: delayed detection represents a loss of opportunity for optimal patient outcomes.

View source

1 of 2

Patients who discontinue the care pathway

Nearly half of patients have previously foregone consulting a dermatologist, often due to excessively long wait times or limited access to care.

View source

Our Mission

How HUVY AI Assists Healthcare Professionals in Skin Cancer Prevention

Prioritize

Screen non-urgent requests to optimize dermatologists' time for critical cases.

Detect Early

Promptly identify suspicious lesions to accelerate referral to dermatologists.

Support

Reassuring and monitoring patients by making detection more accessible, simpler, and faster.

The HUVY Solution

Triage more effectively, in seconds

HUVY AI delivers a standardized, artificial-intelligence-based assessment of pigmented skin lesions in just seconds, directly usable during consultations, in pharmacies, or during home visits. It allows you to objectify referral decisions, prioritize urgent cases, and reduce unnecessary referrals to dermatologists.

Watch the video
Result

You gain clinical peace of mind, your patients are referred earlier, and dermatologists receive the cases that truly require specialist care.

9:41
Nouvelle analyseDUPONT Marie · 45 years old · Left forearm
Image dermoscopique d’une lésion bénigne
Dermoscopie x10
Centrez la lésion dans le cercle

Performance and Safety

A reliable and secure device

Performance established through 4 clinical studies conducted in collaboration with Nantes University Hospital, evaluating over 3,000 lesions.

HUVY is CE-certified Class IIb by an independent notified body and audited annually. It does not provide a diagnosis; rather, it delivers a reliable risk score that assists healthcare professionals in referring their patients at the right time.

Results in 15 seconds, with automatically generated report and referral letter

Data hosted in France on an HDS-certified sovereign cloud, GDPR compliant

Healthcare professional using a dermatoscope to examine a skin lesion

25,000

25,000

tests performed

tests performed

≈ 400

≈ 400

trained healthcare professionals

trained healthcare professionals

Ils nous font confiance

Video

Discover HUVY in pictures

Awards and Certifications

An Award-Winning Trajectory

  1. 2023Concours ÉmergenceNantes Métropole
  2. 20232e Prix Bertrand PivinFondation Polytechnique Paris
  3. 2024Labels DeepTech et JEIInnovation et R&D
  4. 20262e Accélérateur PréventionBpifrance
  5. 2026Next Gen Leaders en SantéFrench Care
  6. 2026Coup de cœur du jury et Prix InnovationPharmagora Plus
  7. 2026Palmarès TIME France HealthInnovation en dispositifs médicauxLire l’article

Frequently Asked Questions

Frequently Asked Questions About HUVY and Melanoma

All Frequently Asked Questions

HUVY is the first Class IIb CE-marked medical device in Europe designed to assist in melanoma risk assessment using artificial intelligence. It is intended for primary healthcare professionals: pharmacists, general practitioners, nurses, and coordinated care organizations. HUVY does not provide a diagnosis; it offers referral guidance based on a reliable risk score.

No. HUVY integrates into the existing care pathway: pharmacist, then primary care physician, and finally a dermatologist if needed. The AI provides a risk level, but the healthcare professional remains the decision-maker, and the diagnosis remains a medical act. The objective is to refer high-risk lesions earlier and reassure patients whose lesions present a low risk.

96% sensitivity and 72% specificity, established through 4 clinical studies conducted in collaboration with the Nantes University Hospital: 3 pre-market studies involving over 3,000 lesions and 1 post-market study of 1,500 cases. Performance data is published in JEADV Clinical Practice. Development is overseen by an independent scientific committee of academic dermatologists.

Yes. The data is hosted on a sovereign cloud on HDS-certified (Health Data Hosting) servers, in compliance with GDPR.

In pharmacies, the analysis is currently not covered by national health insurance. The recommended price is €20 to €25, and certain complementary health insurance plans may cover it—please check with your provider. At a physician's office, the analysis is performed during the consultation.

Are you a healthcare professional? Subscription options are detailed on the Pharmacists and General Practitioners pages.

We answer your questions

We answer your questions

Have a question about HUVY or our solutions? Schedule a video consultation with our team, or leave your contact information to request a callback.

Contact Us
Book a demo